

By Sean Hosein .

Liquorice for AIDS

Scientists in Japan have extracted the substance glycyrrhizin (GL) from liquorice root and found that it has potent anti-viral activity. In addition to its anti-herpes effects, GL strongly inhibited the formation of a certain enzyme which helps HIV enter cells. The drug also prevented cell to cell infection, reducing the formation of giant clusters of infected cells. Antiviral Research 1988;10:289-298.

suggest that when given in high doses (800 to 1600 mg/day) to PLWAs, it increased the T4 count and reduced levels of HIV-1. IV Intl. Conf. AIDS. Stockholm, Sweden, 1988. Abstract #3534. Glycyrrhizin can be bought in certain health food stores in Canada. Results from a small study of GL

Immune Boosters: Levamisole

Placenta and tumour cells produce another type of ferritin called PLF. PLF has been shown to suppress the immune system and also to reduce the formation of new blood cells.

Levels of PLF were highest in people with swollen lymph nodes/spleens in early HIV infections. have found that as HIV infection worsens levels of ferritin rise. Placenta and tumour cells produce Ferritin is a protein which is ed to store iron in cells. Scientists

tion but once the disease progressed, PLF levels dropped. In people with AIDS, PLF levels had fallen to near normal levels. The scientists discovered that PLF binds to T8 cells possibly inactivating them. When PLF coated T8 cells from HIV infected people were treated with the drug levamisole, the PLF was removed.

It is known that certain T8 cells can block HIV infection as well as viral replication. Removing PLF from T8 cells with levamisole could made by Janssen pharmaceuticals help the body in its battle with HIV AIDS 1989;3:11-16. Levamisole is

Infection Fighters: Aerosolized Pentamidine for PCP

pentamidine can delay relapse by six months and reduce the relapse rate by 50%. Significantly, the researchers did not conduct a placebo trial because they consider such trials to be unethical. They used historical controls for comparison.

Aerosolized pentamidine (AP) after studying a group of 102 patients concluded that inhaled relapse occurs within twelve months. Doctors in San Francisco of PLWAs, in half these people a PCP (Pneumocystis carinii eumonia) develops in about 80%

the amount absorbed by the rest of the body. 'Ultravent' nebulizers were used to aerosolize 300 mg of pentamidine dissolved in 4 l of sterile water, delivered over 20 minutes with a compressed air flow Aerosolized pentamidine (AP) maximizes the amount of drug reaching the lungs and minimizes the amount absorbed by the rest of the body. 'Ultravent' nebulizers

aerosol irritating were given inhaled metaproterenol before the AP.
The AP was given once a month. Six patients acquired PCP while on the monthly schedule.
One died to

for people who had a prior episode of PCP. One died from PCP and ten died from other causes. By the sixth month PCP-free survival was 82%

Another result of the trial was that after six months on AP, the proportion of patients who developed PCP while on AZT did not differ significantly from non-AZT users. No side effects were seen when AZT and AP were used together. Lancet 1989;1:654-657.

Meanwhile in other news about AP, researchers in New York have found that the distribution of the drug in the lungs was more uniform when the person was lying flat on his/her back. American Review of Respiratory Diseases 1989;139:A248.

Help for Septra allergies

other allergies, the researchers gave their patients increasing doses of the drug over a period of 26 days until they could tolerate the required dose. While there were relapses, this method might allow more PLWAs to use and benefit from the drug. Annals of Allergy 1989;62:177-179. The standard treatment for PCP is use of the drug septra/bactrim. Unfortunately many PLWAs are allergic to this very effective drug. Now scientists at the National Institutes of Health in the USA have found a way to help patients over-come their allergies. Borrowing a classic method used for treating

Combination therapy for MAC

isoniazid was discontinued. Therapy was continued until death. Doctors found that early and aggressive therapy whenever MAC infected the lungs usually prevented it from spreading. Recent test tube studies show that the drug ciprofloxacin is effective against some strains of MAC. According to in a review of treatment given to 45 patients with AIDS or ARC found that combination therapy helped the patients improve the quality of their lives. The patients were all given the same treatment: isoniazid 300 mg, ethambutol 15 mg/kg, ansamycin 150 mg and clofazimine 100 mg. If liver toxicity developed (Mycobacterium avium complex) infections of the lungs/liver and/or bone marrow. Doctors in New York in combination therapy for MAC. Journal of Infectious Diseases 1989; 159:784-787. the scientists, future therapy might replace isoniazid with ciprofixacin Approximately 1/3 of PLWAs have been found to have MAC

Fluconazole for Thrush

Infections by the fungus candida is often seen in HIV infected people. At times the fungus can be difficult to treat. One drug used to treat wide spread fungal infections, keto-


Fluconazole is an antifungal made by Pfizer. The drug is well absorbed orally and lasts a long time in the blood (a half life of 30 hrs). Preliminary results from a study of 95 patients in Switzerland show that it was well tolerated and effective when given in a single dose

Results were reported on the first 31 patients. Most of the patients (96%) persisted with a good response by the 7th day. 10 patients had a recurrence in signs and symptoms but responded well to a second dose of 150 mg. No side effects were seen. Journal of Infectious Diseases 1989;159;806-807.

between the state of the immune system and that chemical during HIV infection. It should be noted that around the time of seroconversion (when previously HIV antibody negative people begin to produce HIV antibodies, i.e. test "positive" for the antibody) a person can have high levels of T4 cells Neopterin is a substance produced by cells of the immune system—such as macrophages—during inflammatory disorders including viral and parasitic infeccluding viral and parasitic infec-tions as well as cancer. Scientists in California have noticed a relation Testing: Neopterin and AIDS ability of developing AIDS rose significantly. A person with a T4 count of less than 250 and a neopterin level of less than 20 nmol/L had a 58% chance of developing AIDS. Persons with a similar T4 count who had neopterin values greater than 20 nmol/L had a 90% chance chance of developing AIDS within three years based on their levels of neopterin. The prediction became more accurate when T4 cells were used together with blood levels of neopterin to make the analysis. As the T4 count decreased and the neopterin level increased, the prob-

terin may be a quick way of determining the effect of anti-viral drugs in HIV infected people. Journal of Acquired Immune Deficiency Syndromes 1989;2:70-76. According to researchers, measuring the blood levels of neop-

of developing AIDS within three




Co-factors: a new virus

agent (VLIA) derived from a Kaposi's sarcoma lesion from a PLWA. Dr. Lo and his team purified the virus and injected it into 4 silver leaf-monkeys with striking results. All four animals developed weight loss, swollen lymph glands and died within 7 to 9 months. The virus also appeared to cause brain damage. Autopsies of the monkeys showed no opportunistic infections or cancers. IV Intl. Conference on AIDS, Stockholm, Sweden 1988. At the Stockholm conference on AIDS in 1988, Dr. S-C. Lo presented an abstract on a virus like infectious agent (VLIA) derived from a Ka-Abstract #2662.

Now Dr. Lo and his team have discovered VLIA in PLWAs. Using the state-of-the-art PCR (Polymerase Chain Reaction) to detect the virus, researchers have found VLIA in seven out of ten people. The virus was detected in the spleen, liver, lymph nodes, KS lesions and certain blood cells of PLWAs. VLIA was not found in similar sites in five non-HIV infected people. The scientists think that VLIA may be either an opportunistic infection or a co-factor in people with severe HIV infection. Am. J. Trop. Med. Hyg. 1989; 40: 213-226

SCHENERO MERICAN



January 1987